These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 849303)

  • 1. A bicyclo-somatostatin analog, highly specific for the inhibition of growth hormone release.
    Sarantakis D; Teichman J; Clark DE; Lien EL
    Biochem Biophys Res Commun; 1977 Mar; 75(1):143-8. PubMed ID: 849303
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel cyclic undercapeptide, WY-40, 770, with prolonged growth hormone release inhibiting activity.
    Sarantakis D; Teichman J; Lien EL; Fenichel RL
    Biochem Biophys Res Commun; 1976 Nov; 73(2):336-42. PubMed ID: 999714
    [No Abstract]   [Full Text] [Related]  

  • 3. Common structural features for cytoprotection activities of somatostatin, antamanide and related peptides.
    Kessler H; Gehrke M; Haupt A; Klein M; Müller A; Wagner K
    Klin Wochenschr; 1986; 64 Suppl 7():74-8. PubMed ID: 2882054
    [No Abstract]   [Full Text] [Related]  

  • 4. Superactive octapeptide somatostatin analogs containing tryptophan at position 1.
    Cai RZ; Karashima T; Guoth J; Szoke B; Olsen D; Schally AV
    Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2502-6. PubMed ID: 2882520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vivo assay of antisomatotropic activity of somatostatin and two of its analogs].
    Franchimont P; Ghys A; Brison J; Haze-Hagelstein MT; Detournay JM; Dremier C; Scarso A; Demoulin A; Dirkx J
    C R Seances Soc Biol Fil; 1977; 171(3):673-8. PubMed ID: 144010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cylic and linear forms of somatostatin in the inhibiton of growth hormone, insulin and glucagon Secretion.
    Leblanc H; Yen SS
    J Clin Endocrinol Metab; 1975 May; 40(5):906-8. PubMed ID: 1127098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells.
    Moore SB; van der Hoek J; de Capua A; van Koetsveld PM; Hofland LJ; Lamberts SW; Goodman M
    J Med Chem; 2005 Oct; 48(21):6643-52. PubMed ID: 16220980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW
    Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of a nonreducible cyclic analog of somatostatin having only growth hormone release inhibiting activity.
    Garsky VM; Clark DE; Grant NH
    Biochem Biophys Res Commun; 1976 Dec; 73(4):911-6. PubMed ID: 15625860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activity of glycosylated analogs of somatostatin.
    Lavielle S; Ling N; Brazeau P; Benoit R; Wasada T; Harris D; Unger R; Guillemin R
    Biochem Biophys Res Commun; 1979 Nov; 91(2):614-22. PubMed ID: 518658
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthesis and biological activity of highly potent heptapeptide analogs of somatostatin with C-terminal modifications.
    Janecka A; Zubrzycka M
    Endocr Regul; 2001 Jun; 35(2):75-9. PubMed ID: 11563935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies.
    Osapay G; Prokai L; Kim HS; Medzihradszky KF; Coy DH; Liapakis G; Reisine T; Melacini G; Zhu Q; Wang SH; Mattern RH; Goodman M
    J Med Chem; 1997 Jul; 40(14):2241-51. PubMed ID: 9216843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of the duration of inhibition of growth hormone release by Nalpha-acylated-des-(Ala1-Gly2)-H2somatostatin analogs.
    Brown M; Rivier J; Vale W; Guillemin R
    Biochem Biophys Res Commun; 1975 Jul; 65(2):752-6. PubMed ID: 807218
    [No Abstract]   [Full Text] [Related]  

  • 14. D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule.
    Rivier J; Brown M; Vale W
    Biochem Biophys Res Commun; 1975 Jul; 65(2):746-51. PubMed ID: 1096897
    [No Abstract]   [Full Text] [Related]  

  • 15. Structure activity studies on somatostatin.
    Sarantakis D; McKinley WA; Jaunakais I; Clark D; Grant NH
    Clin Endocrinol (Oxf); 1976; 5 Suppl():275S-278S. PubMed ID: 1052780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged suppression of pituitary and pancreatic hormone release by a somatostatin analog.
    Lien EL; Fenichel RL; Grant NH; Boxill GC; Greenwood J; Yardley JP
    Biochem Biophys Res Commun; 1977 Aug; 77(4):1317-25. PubMed ID: 143285
    [No Abstract]   [Full Text] [Related]  

  • 17. Conformational energy studies of the growth hormone inhibitor, cyclo (Aha-Cys-Phe-D-Trp-Lys-Thr-Cys).
    Momany FA
    Biochem Biophys Res Commun; 1980 Jul; 95(1):61-6. PubMed ID: 6106477
    [No Abstract]   [Full Text] [Related]  

  • 18. Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release.
    Meyers C; Arimura A; Gordin A; Fernandez-Durango R; Coy DH; Schally AV; Drouin J; Ferland L; Beaulieu M; Labrie F
    Biochem Biophys Res Commun; 1977 Jan; 74(2):630-6. PubMed ID: 836315
    [No Abstract]   [Full Text] [Related]  

  • 19. Somatostatin analogs with improved oral bioavailability.
    Nutt RF; Colton CD; Veber DF; Slater EL; Saperstein R
    Klin Wochenschr; 1986; 64 Suppl 7():71-3. PubMed ID: 2882053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activity of a cyclic pseudohexapeptide analog of somatostatin.
    Gero TW; Spatola AF; Torres-Aleman I; Schally AV
    Biochem Biophys Res Commun; 1984 May; 120(3):840-5. PubMed ID: 6145411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.